Insulin in endometrial carcinoma chemotherapy: A beneficial addition and not a problem

  • Huilan Sha (沙慧兰)
  • Yanhui Li (李艳辉)
  • Xuan Du (杜 璇)
  • Hongbo Wang (汪宏波)
Article

Summary

The effects of insulin or insulin in combination with chemotherapeutic drugs on the proliferation and apoptosis of endometrial carcinoma cells were examined with an aim to determine the efficacy and safety of insulin in endometrial cancer therapy. Ishikawa and Hec-1A cells were treated with insulin and/or paclitaxel. Cell proliferation was assessed by MTT assay. Cell cycle and cell apoptosis were determined by flow cytometry (FCM). Survivin gene expression was detected by RT-PCR. Our results showed that in a certain range of working concentrations and action time, insulin could mildly augment cell proliferation and the percentage of S phase cells in endometrial cancer (Ishikawa/Hec-1A) cells. Insulin plus paclitaxel (combination group) could significantly inhibit cell proliferation (69.38%±2.32% vs 40.31%±4.52% with Ishikawa; 64.11%±6.33% vs 45.89%±3.27% with Hec-1A) and increase cell apoptosis compared with treatment with paclitaxel alone (paclitaxel group). Survivin gene expression was also significantly decreased in combination group as compared with paclitaxel group. We are led to conclude that insulin can mildly augment cell proliferation and present chemotherapy sensitivity in endometrial cancer cells. Insulin can be to used safely and efficiently in endometrial cancer therapy.

Key words

insulin chemotherapy sensitivity endometrial cancer apoptosis proliferation cell cycle survivin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Cancer Society. Cancer Facts & Figures 2006. American Cancer Society, 2006Google Scholar
  2. 2.
    Shiozawa T, Konishi I. Early endometrial carcinoma: clinicopathology, hormonal aspects, moleculargenetics, diagnosis, and treatment. Int J Clin Oncol, 2006,11(1): 13–21CrossRefPubMedGoogle Scholar
  3. 3.
    Saltzman BS, Doherty JA, Hill DA, et al. Diabetes and endometrial cancer: An evaluation of the modifying effects of other known risk factors. Am J Epidemiol, 2008,167(5):607–614CrossRefPubMedGoogle Scholar
  4. 4.
    Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem, 2008,114(1):63–70CrossRefPubMedGoogle Scholar
  5. 5.
    Zhao J, Xue FX, Hua SF, et al. Effects of insulin on proliferation and apoptosis of endometrial carcinoma cell. Zhonghua Fu Chan Ke Za Zhi (Chinese), 2007,42(10): 696–700Google Scholar
  6. 6.
    Alabaster O, Vonderharr BK, Shafie SM. Metabolic modification by insulin enhances methotrexate cytoxicity in MCF-7 human breast cancer cells. Eur J Cancer Clin Oncol, 1981,17(11):1223–1228CrossRefPubMedGoogle Scholar
  7. 7.
    Miglietta A, Panno ML, Bozzo F, et al. Insulin can modulate MCF-7 cell response to paelitaxel. Cancer Lett. 2004,209(2):139–45CrossRefPubMedGoogle Scholar
  8. 8.
    Ayre SG, Garcia y Bellon DP, Garcia DP Jr., et al. Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer. Med Hypotheses, 2000,55(4):330–334CrossRefPubMedGoogle Scholar
  9. 9.
    Tangjitgamol S, Anderson BO, See HT, et al. Management of endometrial cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol, 2009, 10(11):1119–1127CrossRefPubMedGoogle Scholar
  10. 10.
    Aoki Y, Watanabe M, Amikura T, et al. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecol Oncol, 2004,94(2):333–339CrossRefPubMedGoogle Scholar
  11. 11.
    Shackney SE, McCormack GW, Cocheral GJ; Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Intern Med, 1978, 89(1):107–121PubMedGoogle Scholar
  12. 12.
    Gullo C, Koh LK, Pang WL, et al. Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling. PLoS One, 2010,5(5):e10845CrossRefPubMedGoogle Scholar
  13. 13.
    van Brussel JP, Oomen MA, Vossebeld PJ, et al. Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine. BJU Int, 2004,93(9):1333–1338CrossRefPubMedGoogle Scholar
  14. 14.
    Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol, 1998,179(1):6–12CrossRefPubMedGoogle Scholar
  15. 15.
    Muti P, Quattrin T, Grant BJ, et al. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol. Biomarkers Prev, 2002,11(11):1361–1368PubMedGoogle Scholar
  16. 16.
    Monaco S, Illario M, Rusciano MR, et al. Insulin stimulates fibroblast proliferation through calcium-calmodulin-dependent kinase II, Cell Cycle. 2009 8(13):2024–30PubMedGoogle Scholar
  17. 17.
    Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des, 2007,13(7):671–686CrossRefPubMedGoogle Scholar
  18. 18.
    Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol, 2002,20(1):42–51CrossRefPubMedGoogle Scholar
  19. 19.
    Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr, 2007, 86(3):s836–s842PubMedGoogle Scholar
  20. 20.
    Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy, Radiother Oncol, 2000,57(1):39–43CrossRefPubMedGoogle Scholar
  21. 21.
    Jordan BF, Grégoire V, Demeure RJ, et al. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res, 2002, 62(12):3555–3561PubMedGoogle Scholar
  22. 22.
    Jordan BF, Beghein N, Crokart N, et al. Preclinical safety and antitumor efficacy of insulin combined with irradiation. Radiother Oncol, 2006,81(1):112–117CrossRefPubMedGoogle Scholar
  23. 23.
    Jeffcoat R, Jame AT. The regulation of desaturation and elongation of fatty acids in mammals. In: Numa S, ed. Fatty Acid Metabolism and its Regulation. Amsterdam: Elsevier Science Publishers, 1984.85–112CrossRefGoogle Scholar
  24. 24.
    Srinivasula SM, Ashwell JD. IAPs: what’s in a name? Mol Cell, 2008,30(2):123–135CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang M, Mukherjee N, Bermudez RS, et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate, 2005,64(3):293–302CrossRefPubMedGoogle Scholar
  26. 26.
    Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis, 2007,28(6):1133–1139CrossRefPubMedGoogle Scholar
  27. 27.
    Guha M, Altieri DC. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle, 2009, 8(17):2708–2710CrossRefPubMedGoogle Scholar
  28. 28.
    Takai N, Miyazaki T, Nishida M, et al. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett, 2002,184(1):105–116CrossRefPubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Huilan Sha (沙慧兰)
    • 1
  • Yanhui Li (李艳辉)
    • 1
  • Xuan Du (杜 璇)
    • 1
  • Hongbo Wang (汪宏波)
    • 1
  1. 1.Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations